Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity
Science Advances · 24.04.2026 · 12 (17)
DOI: 10.1126/sciadv.aea8737 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 24.04.2026. Verfasst von Sergey A Shein und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Immunotherapy. Die Arbeit nennt 118 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NINDS NIH HHS, NIH HHS.
Abstract (Originalsprache)
The major barrier to clinical translation of αCD137 immunotherapy is separating antitumor efficacy from hepatotoxicity driven by IFN-γ–producing CD8 T cells. We propose a strategy to limit toxicity by promoting contraction of excessively expanded CD8 T cells. We identify CD11c + KLRG1 + effector CD8 T cells (CD11c + T E ) as the primary source of IFN-γ, recirculating between blood and secondary lymphoid organs (SLOs), where they undergo apoptosis during contraction. We show that lymphotoxin β receptor (LTβR) signaling restrains this contraction. Mechanistically, lymphotoxin-expressing B cells activate LTβR in fibroblastic reticular cells (FRCs), suppressing apoptosis of CD11c + T E cells in the spleen and sustaining their systemic circulation and liver infiltration. Pharmacological LTβR blockade abrogates hepatotoxicity by reducing the accumulation of IFN-γ–producing CD11c + T E cells while preserving tumor-specific CD8 T cell responses. These findings identify LTβR as a key regulator of effector CD8 T cell persistence and support the use of LTβR antagonists to improve the safety of αCD137-based immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
- Department of Molecular Medicine, UTHSCSA, San Antonio, TX, USA.
- Greehey Children's Cancer Research Institute, San Antonio, TX, USA.
- Department of Population Health Sciences, UTHSCSA, San Antonio, TX, USA.
- Department of Immunology, Mayo Clinic, Phoenix, AZ, USA.
- Institute of Immunobiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
ORCID-Profile: Sergey A Shein, Anna A Korchagina, Li-Ju Wang, Yidong Chen, Jacob S Fisher, Burkhard Ludewig, Jessica N Lancaster, Yang-Xin Fu, Ekaterina Koroleva, Alexei V Tumanov
Förderung
- NIA NIH HHS
- NINDS NIH HHS
- NIH HHS
- NCI NIH HHS
- National Institutes of Health
- National Institute on Aging
- National Cancer Institute
- National Institute of General Medical Sciences
Zitieren
APA
Shein, S. A., Korchagina, A. A., Wang, L. J., Lai, Z., Chen, Y., Fisher, J. S., Ludewig, B., Lancaster, J. N., Fu, Y. X., Koroleva, E., & Tumanov, A. V. (2026). Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity. Science Advances, 12(17). https://doi.org/10.1126/sciadv.aea8737
Vancouver
Shein SA, Korchagina AA, Wang LJ, Lai Z, Chen Y, Fisher JS, et al. Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity. Science Advances. 2026;12(17). doi:10.1126/sciadv.aea8737
BibTeX
@article{Shein2026,
author = {Shein, Sergey A and Korchagina, Anna A and Wang, Li-Ju and Lai, Zhao and Chen, Yidong and Fisher, Jacob S and Ludewig, Burkhard and Lancaster, Jessica N and Fu, Yang-Xin and Koroleva, Ekaterina and Tumanov, Alexei V},
title = {Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {17},
doi = {10.1126/sciadv.aea8737}
}
EUVIMED